A phase I study of panobinostat in combination with ICE (ifosfamide, carboplatin and etoposide) in patients with relapsed or refractory classical hodgkin lymphoma (cHL)

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 2, 2014, Pages 5-6

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; PANOBINOSTAT; ANTINEOPLASTIC AGENT; CISPLATIN; HYDROXAMIC ACID; INDOLE DERIVATIVE;

APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; FEBRILE NEUTROPENIA; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RADIOGRAPHY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; IFOSFAMIDE; INDOLES; MALE; MIDDLE AGED;

EID: 84928704610     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-623.
2. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665-1670.
3. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008;112(4):1424-1433.
4. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197-2203.
5. Sharma S, Beck J, Mita M, et al. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs. 2013;31(4):974-985.
6. Oki Y, Fanale MA, Westin J, et al. A phase I study of panobinostat in combination with ICE (ifosfamide, carboplatin and etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) [ASH abstract 252]. Blood. 2013;122(21 suppl).